"Even 'miracle' drugs like Wegovy or Mounjaro require monitoring and changing one's lifestyle in order to promote sustainable weight loss. Our technology is the missing link between GLP-1 and long-lasting results."
Saskia Korink Romani, Co-Founder & CEO
Why Invest in EW2Health?
GLP-1s are unlocking one of the largest health and consumer markets in history. But without platforms like EW2Health, their long-term impact will be limited. We make GLP-1 therapy sustainable, scalable, and valuable — for patients, clinics, and the entire ecosystem.
A once-in-a-generation healthcare opportunity
-
Explosive growth: GLP-1 drugs (e.g., Ozempic, Wegovy, Mounjaro) generated $50B+ revenue in 2024 and are projected to triple to $156–160B by 2030 (≈17% CAGR) .
-
Consumer pull: In the U.S., 1 in 8 adults has tried a GLP-1 and ~6% are active users — unprecedented penetration for a new obesity treatment .
-
Dominant players: Novo Nordisk and Eli Lilly control >50% of the market, but demand far outstrips supply .
-
Beyond weight loss: Expanding into NASH, sleep apnea, cardiovascular, and neurodegenerative diseases, multiplying market potential.
The challenge: adherence & sustainability
Despite strong efficacy, 40–60% of patients drop out within a year, undermining both health outcomes and drug revenues .
-
Side effects (nausea, GI symptoms) often unmanaged.
-
Minimal follow-up between clinic visits.
-
Lack of integrated lifestyle support → weight regain after discontinuation.
-
High costs and insurance gaps amplify discontinuation .
Without solutions, billions in projected revenue are at risk and patient health benefits are not sustained.
EW2Health: the missing link
A predictive behavioral platform built to safeguard and amplify the GLP-1 market by making treatment durable:
-
Adherence boost: Numberless scales + Predictive Behavioral Analytics improve persistence by >50% .
-
Emotionally safe monitoring: Daily weigh-ins without anxiety → 3.8x/week engagement.
-
Proactive interventions: AI flags early risks, enabling timely support.
-
Integrated care: Bridges pharma, clinics, lifestyle partners, and patients into one scalable ecosystem.
-
Proven outcomes: >2 better results, >15–20% weight reduction; clinics see 25% lower costs and 30% more recurring revenue.
Why invest
-
Picks & shovels of the GLP-1 gold rush: We don’t make the drugs; we make them work better, longer, and more profitably.
-
Global scalability: Addressing a €1T obesity care TAM.
-
Recurring SaaS revenue model: €10–15 per patient/month, plus device and ecosystem revenues.
-
Defensible moat: Clinic-centric, B2B2C model with deep integration vs. direct-to-consumer (D2C) competitors.
-
Social impact: Tackling obesity sustainably for the 2B people affected worldwide.